Kevin recently joined Isogenica from Oxonica plc and brings extensive experience in developing promising technology into commercial businesses in a range of industries. During his tenure at Oxonica he established Oxonica as a leading nanotechnology company. Kevin previously held commercial and technical management roles with Rhodia Consumer Specialties Limited, Albright and Wilson UK Limited and ICI Chemicals & Polymers. He has a DPhil in organic chemistry. Kevin is also a non-executive director of Elementis plc and Chairman of the UK Nanotechnology Knowledge Transfer Network.

Chris joined Isogenica Ltd. in 2002 and has been involved in developing the company’s platform technology, CIS display, for the discovery of polypeptides as research reagents, diagnostic tools and therapeutics. He has over ten years experience within the industry, previously working for a small company, Gendaq Ltd. which was spun out of Sir Aaron Klug’s laboratory at the LMB Cambridge. At Gendaq, Chris led a team of scientists to develop customised transcription factors using engineered zinc finger DNA binding proteins. The team used high throughput techniques to discover DNA recognition codes for these proteins and the company was subsequently acquired by Sangamo Biosciences Inc. for $36.5million (Sangamo Biosciences Inc.). Chris has authored a number of patents and papers at both companies.

Mr. Lundin brings international experience from VBB AB, EKA Chemicals AB, Berol Verkstadskemi AB (part of the Akzo Nobel group) and, most recently, from Diffchamb AB (publ.), of which Mr Lundin was founder and managing director. Mr Lundin also sits on the board of Dunross, one of Isogenica’s major shareholders.

Renny is Executive Chairman of a clinical research consultancy company working with a number of public and venture capital funded companies developing platform technologies and new clinical treatments for common conditions including cancer. He is a Director of the Phase I resourcing company – iResearch - and is currently a non-executive director of several life science companies as well as one of the top performing NHS Foundation Trusts in England known for its pioneering work in maxillofacial and reconstructive surgery, orthodontics, head and neck cancer and burns. Renny is a Trustee of Lord Snowdon’s Award Scheme for disabled students and clinical research advisor to the charity SPARKS. He was previously CEO of a venture capital backed Clinical Research Organisation, Director of Clinical Research at the Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust and has held senior positions with the UK Medical Research Council and the Horsham-based charity Action Medical Research.

Per Norfeldt is a medical doctor specialized in psychiatry, initially with a focus on schizophrenia and psychotic disorders but in later years mainly active in the area of neuropsychiatry and ocd. He has a background in protein chemistry at the Department of Medical and Physiological Chemistry, University of Gothenburg, where he did research on lipoproteins in relation to atherosclerosis. In 2001 he started BIS, offering his services as an independent consultant in pharmaceutical research and biotechnology. Per Norfeldt is a long-standing adviser to the international investment company Dunross & Co and was recently made a board member of Cellectricon, a Swedish company that uses a unique approach of combining microfluidics engineering with biology to enable the development of completely new types of miniaturized real time cell-based screening devises for application in biotechnology, biomedical research and drug discovery.

Professor Leanderson has a medical background as well as a PhD in experimental pathology. He carried out postdoctoral studies at the Basel Institute for Immunology between 1983 and 1986 and was appointed to the Chair of Immunology, Lund University, in 1990. During the last decade he has collaborated with and consulted for a number of pharmaceutical and biotechnology companies. Professor Leanderson is currently CEO of Active Biotech AB (Lund, Sweden).

Mr Eriksson has an MSc in Economics and more than eighteen years of equity and real estate investment experience. He is a Director of Vasastaden Holding AB and represents one of Isogenica's major shareholders.

Dr Kevin FitzGerald is CEO of Anglo-Austrian biopharmaceutical company f-star. Until April 2009, Kevin was CEO of Isogenica which he founded in 2000. During his time with Isogenica, Kevin secured over £6.5m of equity finance, and negotiated and closed deals with a wide range of major life science companies including AstraZeneca, Amgen, Centocor, Pfizer, Wyeth, Johnson & Johnson, GE Healthcare and UCB Celltech. Kevin led Isogenica to a full-year profit of more than £1.1m during 2008. Before establishing Isogenica, Kevin was a member of the senior management team at Actinova Ltd., the UK subsidiary of Active Biotech AB. Prior to this Kevin spent seven years at Cambridge Antibody Technology plc. (acquired by AstraZeneca in 2006) where he was among the founding group of scientists. Kevin studied for his PhD in the laboratory of Sir Greg Winter FRS at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School (awarded with distinction), following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London. Kevin was elected a fellow of the Royal Society of Medicine in 2006.

Anthony brings over twenty years’ senior management experience to Isogenica. After qualifying as a lawyer in 1979, Anthony held a number of in-house legal positions before his appointment as Vice President Operations and Legal Affairs and Company Secretary at the newly formed Cambridge Antibody Technology, where he took the company from start-up to a full listing on the London Stock Exchange.